Veracyte Inc. has announced that the first prospective validation data for a molecular signature predicting hormone therapy benefit in men with recurrent prostate cancer will be presented at the upcoming ASTRO 2025 annual meeting of the American Society for Radiation Oncology. The findings, developed using Veracyte's Decipher GRID research tool, are part of nine Decipher-focused abstracts, including six podium presentations, scheduled for the conference taking place from September 27 to October 1 at the Moscone Center in San Francisco. Among the highlighted studies is a double-blinded, placebo-controlled, biomarker-stratified randomized trial of apalutamide and radiotherapy for recurrent prostate cancer, as well as analyses examining adverse molecular features across large patient cohorts. The results have not yet been presented and are scheduled for presentation during the conference.